The latest report Schizophrenia Pipeline Highlights – 2014 Update, provides most up-to-date information on key pipeline molecules in the global Schizophrenia market. It covers emerging therapies for Schizophrenia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Schizophrenia pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Schizophrenia pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Schizophrenia pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Schizophrenia pipeline products will be launched in the US and Ex-US till 2017.